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Background: The Vpr protein of human immunodeficiency virus type 1 (HIV-1) plays an important role in viral
replication. It has been reported that Vpr stimulates the nuclear factor-κB (NF-κB) and activator protein 1 (AP-1)
signaling pathways, and thereby regulates viral and host cell gene expression. However, the molecular mechanism
behind this function of Vpr is not fully understood.
Results: Here, we have identified transforming growth factor-β-activated kinase 1 (TAK1) as the important upstream
signaling molecule that Vpr associates with in order to activate NF-κB and AP-1 signaling. HIV-1 virion-associated
Vpr is able to stimulate phosphorylation of TAK1. This activity of Vpr depends on its association with TAK1, since
the S79A Vpr mutant lost interaction with TAK1 and was unable to activate TAK1. This association allows Vpr to
promote the interaction of TAB3 with TAK1 and increase the polyubiquitination of TAK1, which renders TAK1
phosphorylation. In further support of the key role of TAK1 in this function of Vpr, knockdown of endogenous TAK1
significantly attenuated the ability of Vpr to activate NF-κB and AP-1 as well as the ability to stimulate HIV-1 LTR
promoter.
Conclusions: HIV-1 Vpr enhances the phosphorylation and polyubiquitination of TAK1, and as a result, activates
NF-κB and AP-1 signaling pathways and stimulates HIV-1 LTR promoter.
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Human immunodeficiency virus type 1 (HIV-1) codes an
accessory protein called viral protein R (Vpr) that all pri-
mate lentiviruses have [1,2]. Vpr is a 14-kDa protein,
and is found in both the cytoplasm and the nucleus of
infected cells [3]. Notably, Vpr is specifically incorpo-
rated into progeny virions through interacting with viral
Gag protein [4-6]. This presence in HIV-1 particles en-
ables Vpr to play important roles at the early stage of
viral infection, such as promoting the nuclear transport
of the viral pre-integration complex (PIC) and enhancing
the fidelity of the reverse transcription [7,8]. In addition,
Vpr has also been reported to induce cell cycle G2/M ar-
rest, regulate apoptosis, transactivate HIV-1 LTR and
affect the production of IL-6, IL-8, and CCL5 [9-18].* Correspondence: juantan@nankai.edu.cn; wentaoqiao@nankai.edu.cn
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unless otherwise stated.These diverse functions of Vpr partially result from its
ability to modulate the activities of cellular factors such
as nuclear factor-κB (NF-κB) and activator protein 1
(AP-1) that are not only essential for multiple important
cellular processes but also for HIV-1 gene expression
[16-19]. However, it is not fully understood how Vpr ex-
erts its effect on NF-κB and AP-1.
The activities of NF-κB and AP-1 are regulated by a
couple of signaling pathways in response to various
stimuli such as cytokines, bacterial and viral infections.
These signal transduction cascades share a key regulator
called TAK1 (transforming growth factor-β-activated
kinase 1), a member of MAPK kinase kinase (MAP3K)
family, that responds to different stimuli and assembles
into a complex including the receptor proximal complex
containing TNF receptor associated factor (TRAF), TAK1
binding protein 1, 2 and 3 (TAB1, TAB2, and TAB3)
[20-26]. Among these TAK1-binding proteins, TAB1 inter-
acts constitutively with the NH2-terminal catalytic do-
main of TAK1 and regulates the oligomerization and
auto-phosphorylation of TAK1 [27-31]. TAB2 or TAB3,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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tions as an adaptor protein to recruit TAK1 to the K63-
linked polyubiquitin chains formed by TRAF6 [24,26,32-35].
TAK1 then initiates the MKK cascade by activating c-Jun
N-terminal kinase (JNK) and p38 MAPK, and stimu-
lates the IκB kinase (IKK) pathway that leads to NF-κB
activation [25,36].
The activity of TAK1 is regulated by phosphorylation
and polyubiquitination. Upon cytokine stimulation,
TAK1 undergoes auto-phosphorylation as a result of as-
sociation with TAB2/3-polyubiquitin chains [37] or
TAB1-dependent oligomerization [30,38]. Phosphoryl-
ation occurs at four conserved serine and threonine resi-
dues within TAK1 activation loop, including Thr-178,
Thr-184, Thr-187, and Ser-192 [28,30,31,39,40], among
which Thr-187 phosphorylation has a major role in regu-
lating TAK1 activity [30,31]. TNFα, IL-1β, and TGFβ
cause K63-linked polyubiquitination of TAK1 by TRAF2
or TRAF6 [41,42]. The ubiquitin acceptor sites have
been mapped to Lys-34, Lys-158, or Lys-209 in a
stimulus-specific manner [41,43-47]. The possible inter-
play between phosphorylation and polyubiquitination of
TAK1 is unclear [37].
In light of its key roles in different signaling pathways, it
is not surprising that TAK1 has become the target of
many viruses in order to modulate the production of pro-
inflammatory cytokines expression for the benefit of virus
replication. In the case of HIV-1, the viral gp41 protein
has been reported to induce TAK1-dependent NF-κB sig-
naling which enhances viral replication in CD4+ T cells
[48]. In this study, we further show that the HIV-1 virion-
associated Vpr activates NF-κB and AP-1 via TAK1-
dependent pathways. This activity of Vpr results from its
association with the TAK1 and consequent stimulation of
TAK1 phosphorylation and polyubiquitination. Our find-
ings not only highlight the essential role of TAK1 in regu-
lating the NF-κB and AP-1 signaling cascades, but also
present one example in regard to how pathogens assimi-
late TAK1 to enhance their multiplication.
Results
Vpr induces the phosphorylation of TAK1
Since TAK1 is the upstream kinase for both NF-κB and
AP-1 signaling pathways, we first asked whether HIV-1
virion-associated Vpr activates NF-κB and AP-1 by
modulating the activity of TAK1. To answer this ques-
tion, we monitored TAK1 activation by measuring its
auto-phosphorylation at the major phosphorylation site
Thr-187 [31]. We utilized the same amounts of VSV-G
pseudotyped NLENY1-ES-IRES (WT for short) and
NLENY1-ΔVpr (ΔVpr for short) viruses (Figure 1A) to
infect the CD4+ T cells called Jurkat and harvested the
infected cells 2 hours after infection before viral proteins
were newly synthesized. Cells were treated with 15 nMCalyculin A (a serine/threonine phosphatase inhibitor of
both PP1 and PP2A families) for 5 min prior to harvest
in order to preserve the phosphorylated TAK1 mole-
cules. Levels of total endogenous TAK1 and its phos-
phorylated form were assessed by Western blotting.
Results of Figure 1B confirmed that the WT, not ΔVpr
viruses, carried Vpr protein. In contrast to the ΔVpr
virus, infection of the WT virus significantly increased
phosphorylation of endogenous TAK1 (Figure 1B).
To rule out the possible effect of viral genome, we
tested Vpr-induced phosphorylation of TAK1 in the
presence of a reverse transcriptase inhibitor named AZT
(10 μM). The results showed that under AZT treatment,
the WT virus, but not the ΔVpr virus, still greatly en-
hanced TAK1 phosphorylation (Additional file 1: Figure
S1A). In addition, we also performed TAK1 phosphoryl-
ation assay with HIV-1 VLP. We first produced VSV-G
pseudotyped HIV-1 VLP (without the genome) by trans-
fecting HEK293T cells with the pVSV-G (encoding the
glycoprotein of VSV), pLP1 (encoding Gag and Gag-
Pol), pLP2 (encoding Rev) together with pcDNA3.1 or
pcDNA3-Vpr DNA. Results of Western blotting showed
that HIV-1 VLP (Vpr+), but not HIV-1 VLP (Vpr-) car-
ried Vpr (Additional file 1: Figure S1B). Next, we used
the same p24 amounts of HIV-1 VLP (Vpr+) or HIV-1
VLP (Vpr-) to infect Jurkat cells. Results of Additional
file 1: Figure S1C show that phosphorylation of TAK1
was markedly increased following infection by the HIV-1
VLP (Vpr+) but not by HIV-1 VLP (Vpr-).
Furthermore, we also observed an enhancement of
TAK1 phosphorylation by Vpr in the monocyte cell line
called THP-1 (Figure 1C) and THP-1 differentiated
macrophage (Figure 1D). To validate this observation, we
isolated peripheral blood mononuclear cells (PBMCs)
from healthy donors and examined TAK1 phosphoryl-
ation upon infection by the wild type or ΔVpr HIV-1. The
results showed that the WT virus, but not the ΔVpr virus,
profoundly increased TAK1 phosphorylation (Figure 1E).
In order to further demonstrate that it is Vpr, not other
HIV-1 proteins, that caused TAK1 phosphorylation, we
transfected HEK293T or HeLa cells with plasmid DNA that
expressed Myc-TAK1 and Flag-Vpr. TAB1 overexpression
is known to stimulate TAK1 phosphorylation and was used
as a positive control. The results showed that Flag-Vpr
markedly enhanced the phosphorylation of TAK1 in both
HeLa and HEK293T cells (Figure 2A and B). We also ob-
served Vpr-induced phosphorylation of endogenous TAK1
in HEK293T cells (Figure 2C). Taken together, these data
suggest that Vpr increases the phosphorylation of TAK1 at
the early stage of HIV-1 infection.
Vpr associates with TAK1
We next asked whether Vpr enhances TAK1 phosphoryl-
ation through association with TAK1. We first transfected
Figure 1 Vpr enhances the phosphorylation of TAK1 following HIV-1 infection. (A) Schematic representation of NLENY1-ES-IRES and
NLENY1-ΔVpr viruses. A mutated start codon of vpr gene was introduced in NLENY1-ES to generate NLENY1-ΔVpr. (B-D) Virion-associated
Vpr enhances the phosphorylation of TAK1 on Thr-187 in HIV-1 permissive cells. A total of 2 × 106 Jurkat cells (B), THP-1 cells (C), and THP-1
differentiated macrophage-like cells (D) were infected with VSV-G pseudotyped WT or ΔVpr viruses equivalent to 500 ng p24 in the presence of 5
μg/ml polybrene by spinoculation at 300 xg for 30 min. After another 1.5 hours, cells were pretreated with 15 nM Calyculin A for 5 min. Then cells
were harvested by centrifugation at 1000 × g for 3 min at 4°C, washed twice with ice-cold 1xphosphate-buffered saline, lysed in 70 μl lysis buffer,
and chilled on ice for 30 min with frequent agitation. Whole cell lysates were subjected to Western blotting and probed with anti-phospho-TAK1
(Thr-187), rabbit anti-TAK1, anti-p24, anti-Vpr, and anti-Tubulin antibodies. (E) Human peripheral blood mononuclear cells (PBMCs) were isolated
from healthy blood donors. PBMCs were activated with phytohemagglutinin (PHA; 5 mg/ml) and IL-2 (20 U/ml) for 24 h, followed by infection
with VSV-G pseudotyped WT or ΔVpr (equivalent to 500 ng p24) in the presence of 5 μg/ml polybrene by spinoculation at 300 xg for 30 min.
After two hours, cells were pretreated with 15 nM Calyculin A for 5 min. Whole cell lysates were examined in Western blotting with the indicated
antibodies.
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Figure 2 Vpr enhances the phosphorylation of TAK1 in HeLa and 293T cells. (A-B) Vpr induces the phosphorylation of exogenous TAK1 in
a dose-dependent manner. HeLa cells (0.25 × 106) (A) and HEK293T (0.5 × 106) (B) were transfected with 0.3 μg Myc-TAK1 and increasing amounts
of Flag-Vpr, or 0.3 μg HA-TAB1. Different amounts of Vpr plasmid were transfected into HEK293T cells (0, 0.2, 0.5 and 1 μg) and HeLa cells (0, 0.5,
1, and 1.5 μg). Forty-eight hours after transfection, whole cell lysates were harvested and probed with indicated antibodies. (C) Vpr induces the
phosphorylation of endogenous TAK1. HEK293T cells were transfected with 1 μg Flag-Vpr or an empty vector. After forty-eight hours, cells were
pretreated with DMSO or 20 nM Calyculin A for 5 min. Whole cell lysates were subjected to Western blotting and probed with indicated antibodies.
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Myc-TAK1, and performed co-immunoprecipitation ex-
periments with anti-Myc or anti-Flag antibody. The re-
sults showed that Flag-Vpr was co-immunoprecipitated
with Myc-TAK1 (Figure 3A). We also observed that
Flag-Vpr was reciprocally immunoprecipitated with en-
dogenous TAK1 (Figure 3B). In further support of the
association between Vpr and TAK1, Vpr was found to
partially co-localize with TAK1 in the perinuclear region
(Figure 3C). Together, these data demonstrate an associ-
ation of Vpr with TAK1.
TRAF6 is required for Vpr-induced TAK1 phosphorylation
Given the dependence of TAK1 phosphorylation on
TRAF6-mediated TAK1 polyubiquitination [41], we
asked whether TRAF6 is needed for Vpr-induced TAK1
phosphorylation. To answer this question, we first gener-
ated two lentiviral vectors that express TRAF2- or
TRAF6-specific shRNA. A non-specific scrambled shRNA
was used as the control. We then examined whether
virion-associated Vpr was still able to enhance TAK1
phosphorylation when TRAF6 or TRAF2 was knocked
down in Jurkat cells. Results of Western blotting showed
that endogenous TRAF6 and TRAF2 were effectively
knocked down (Figure 4A). Knockdown of endogenous
TRAF6 blocked the phosphorylation of TAK1 and ablated
the stimulating effect of Vpr (Figure 4A). In contrast,
knockdown of TRAF2 did not prevent Vpr from activating
TAK1. These data indicate that TRAF6 is required for
Vpr-induced TAK1 phosphorylation. In order to further
demonstrate the dependence of Vpr-stimulated TAK1
phosphorylation on TAK1 polyubiquitination, we mutated
each of the ubiquitin acceptor sites in TAK1, includingLys-34, Lys-158, and Lys-209 that have been reported in
the literatures [41,43-47]. The results of Figure 4B showed
that mutations K158R and K209R, but not K34R, abro-
gated TAK1 polyubiquitination. This defect in polyubiqui-
tination correlated with the loss of TAK1 phosphorylation.
Importantly, as opposed to increasing the phosphorylation
of wild type and K34R TAK1, Vpr was unable to render
the K158R and K209R mutants phosphorylated (Figure 4C).
Together, we conclude that Vpr promotes TAK1 phos-
phorylation through modulating TRAF6-mediated poly-
ubiquitination of TAK1.
Vpr increases the polyubiquitination of TAK1
Given the association of TAK1 polyubiquitination with
Vpr-induced TAK1 phosphorylation, we postulate that
Vpr may regulate TAK1 activity through modulating
TAK1 polyubiquination. Indeed, expression of Vpr
modestly increased the level of TAK1 polyubiquitination
(Figure 5A), which is comparable to the increase that
was caused by the overexpression of TAB3 that is re-
sponsible for recruiting TAK1 to the K63-linked polyubi-
quitin chains. Interestingly, co-expression of Vpr and TAB3
further increased TAK1 polyubiquitination (Figure 5A).
This stimulating effect of Vpr on TAK1 polyubiquiti-
nation may result either from augmenting the enzymatic
activity of TRAF6 or facilitating the recruitment of
TAB2 or TAB3 to TAK1. It is known that TRAF6 under-
goes auto-polyubiquitination. Results of Figure 5B showed
that Vpr had no effect on this event, suggesting that the
enzymatic activity of TRAF6 is not affected by Vpr. We
next immunoprecipitated TAK1 and examined the pres-
ence of other components of the TAK1 complex. The re-
sults showed that Vpr markedly increased the level of
Figure 3 Vpr associates with TAK1. (A) HEK293T cells (4 × 106) were co-transfected with Myc-TAK1 and Flag-Vpr. Co-immunoprecipitation was
performed with indicated antibodies. Samples from both cell lysates and immunoprecipitates were subjected to Western blotting and probed
with rabbit anti-TAK1 and mouse anti-Flag antibodies. (B) Vpr associates with endogenous TAK1. Lysates of Flag-Vpr-expressing HEK293T cells
(4 × 106) were immunoprecipitated with control mouse IgG and mouse anti-TAK1 (left) or anti-Flag (right) antibodies. Samples from both cell
lysates and immunoprecipitates were subjected to Western blotting. (C) Vpr co-localizes at least in part with TAK1. HeLa cells (0.1 × 106) were
transfected with Flag-Vpr and/or Myc-TAK1 plasmid DNA. Indirect IFA was used to localize Vpr (with rabbit anti-Flag antibody and FITC-conjugated
goat anti mouse secondary antibody) and TAK1 (with mouse anti-Myc antibody and TRITC-conjugated goat anti mouse secondary antibody).
Nuclei were visualized with DAPI staining. Representative images are shown.
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Figure 4 TRAF6 is required for Vpr-induced TAK1 phosphorylation. (A) Jurkat cells (2 × 106) were transduced with retroviruses expressing
shRNA targeting TRAF6, TRAF2 or a scrambled shRNA (shControl). After forty-eight hours, cells were exposed to VSV-G pseudotyped WT or ΔVpr
(equivalent to 500 ng p24) in the presence of 5 μg/ml polybrene by spinoculation at 300 xg for 30 min. After two hours, cells were pretreated
with 15 nM Calyculin A for 5 min. Whole cell lysates were examined in Western blotting with the indicated antibodies. (B) HEK293T cells (4 × 106)
were co-transfected with wild type TAK1 or its mutants (K34R, K158R, K209R) with or without HA-Ub DNA constructs. Forty-eight hours after
transfection, cells were collected and denatured by boiling with 1% SDS, followed by immunoprecipitation with anti-Myc antibody. Polyubiquitination
of TAK1 was detected with anti-HA antibody. Samples from both cell lysates and immunoprecipitates were probed with anti-TAK1 antibody. (C)
Polyubiquitination of TAK1 is required for Vpr-induced TAK1 phosphorylation. HEK293T cells (0.5 × 106) were transfected with 0.3 μg Myc-TAK1 or its
mutants (K34R, K158R, K209R) along with empty vector or 0.5 μg Flag-Vpr. After forty-eight hours, whole cell lysates were subjected to western blotting
and probed with indicated antibodies.
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on TAB1 and TAB2 (Figure 5C). This increase in TAB3
recruitment correlated with enhanced phosphorylation of
TAK1 (Figure 5C). Since TAB3 interacts with both TAK1
and TRAF6, we conclude that Vpr augments the inter-
action of TAB3 with TAK1, consequently increases
TRAF6-mediated polyubiquination and phosphorylation
of TAK1. This key role of TAB3 in Vpr-induced phos-
phorylation of TAK1 is further demonstrated by the re-
sults of Figure 5D showing that knockdown of TAB3 in
HeLa cells drastically reduced TAK1 phosphorylation and,
more importantly, prevented Vpr from upregulating
TAK1 phosphorylation.
Activation of TAK1 by Vpr stimulates the NF-κB and AP-1
signaling
IKKβ and MKK7 are two substrates of TAK1. Since Vpr
activates TAK1, we expected that Vpr increases the phos-
phorylation of IKKβ and MKK7 by TAK1. Indeed, overex-
pression of either Vpr or TAK1 upregulated the
phosphorylation of IKKβ (Figure 6A). A higher level ofIKKβ phosphorylation was detected when Vpr and TAK1
were co-expressed (Figure 6A). Although we did not de-
tect an increase in MKK7 phosphorylation when Vpr itself
was overexpressed, significant phosphorylation of MKK7
was observed with TAK1 overexpression and this level of
MKK7 phosphorylation was further increased by Vpr
(Figure 6B). Together, these data indicate that activation
of TAK1 by Vpr leads to activation of IKKβ and MKK7.
It is known that phosphorylation of IKKβ and MKK7
causes relocation of NF-κB and AP-1 into the nucleus,
respectively, and leads to upregulation of genes whose
promoters contain the binding sequences for NF-κB or
AP-1. It is thus not surprising that Vpr enhances the ex-
pression of luciferase that reports the activation of NF-
κB or AP-1 (Figure 6D and E, column 1). Importantly,
knockdown of TAK1, TRAF6, or TAB3 (Figure 6C) sig-
nificantly diminished the ability of Vpr to activate NF-
κB- or AP-1-dependent luciferase expression (Figure 6D
and E). We also observed that activation of HIV-1 LTR
promoter by Vpr was also attenuated as a result of
knockdown of TAK1, TRAF6 or TAB3 (Figure 6F).
Figure 5 Vpr increases the polyubiquitination of TAK1. (A) Vpr synergizes with TAB3 to induce the polyubiquitination of TAK1. HEK293T cells
(4 × 106) were transfected with Myc-TAK1 together with Flag-Vpr, T7-TAB3 or HA-Ub. Forty-eight hours after transfection, cells were harvested
and polyubiquitination of the immunoprecipitated TAK1 was detected in Western blotting with anti-HA antibody. (B) Vpr does not affect the
auto-ubiquitination of TRAF6. HEK293T cells (4 × 106) were transfected with HA-TRAF6 together with Vpr or Ub DNA. Cell lysates were immunoprecipitated
with anti-HA antibody. Samples from both cell lysates and immunoprecipitates were probed with indicated antibodies. (C) Vpr promotes the
association between TAK1 and TAB3. A total of 1 × 107 HEK293T cells were transfected with an empty vector or Flag-Vpr DNA construct. After
forty-eight hours, cells were pretreated with 20 nM Calyculin A for 5 min. Then whole cell lysates were immunoprecipitated with anti-TAK1
antibody. Samples from both cell lysates and immunoprecipitates were probed with rabbit anti-TAK1, anti-TAB1, anti-TAB2, anti-TAB3, anti-Flag,
and anti-Tubulin antibodies. (D) TAB3 is involved in Vpr-induced phosphorylation of TAK1. The control and TAB3-knockdown HeLa cell lines
(0.25 × 106) were transfected with 1 μg empty vector or Flag-Vpr DNA constructs. After 48 hours, cells were pretreated with 20 nM Calyculin A
for 5 min before cells were collected and analyzed by Western blotting with indicated antibodies.
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tion in TAK1-knockdown THP-1 cells. We first mutated
the translation start codon of Vpr in the context of the
HIV-Luc proviral DNA and generated HIV-Luc ΔVpr.
We then produced VSV-G pseudotyped HIV-1 virus par-
ticles by transfecting HEK293T cells. As expected, the
HIV-Luc virus, but not HIV-Luc ΔVpr, expressed Vpr(Additional file 1: Figure S2A). We used the same amount
of these two viruses (equivalent to 2 ng p24) to infect
TAK1-knockdown THP-1 cells (Additional file 1: Figure
S2B). The infection of HIV-1 was assessed by measuring
the luciferase activities of infected cells. Depleting en-
dogenous TAK1 diminished the replication of HIV-Luc
virus by 2-fold, whereas the infection of HIV-Luc ΔVpr
Figure 6 TAK1 is required for Vpr-induced activation of NF-κB and AP-1 signaling. (A-B) Vpr promotes TAK1-mediated phosphorylation
of IKKβ and MKK7. HEK293T (0.5 × 106) were transfected with 0.3 μg HA-IKKβ (A) or 0.5 μg HA-MKK7 (B), with or without Myc-TAK1 and Flag-Vpr
DNA constructs. After forty-eight hours, whole cell lysates were subjected to Western blotting and probed with indicated antibodies. (C) Expression of
TAK1, TAB3, and TRAF6 in HeLa knockdown cell lines. Retroviruses coding shControl, TAK1, TAB3, or TRAF6 shRNA sequences, were stably transduced
into HeLa cells. Cell lysates were immunoblotted with indicated antibodies. (D-F) Endogenous TAK1, TRAF6, and TAB3 are required for activation of
NF-κB, AP-1, and HIV-1 LTR by Vpr. The aforementioned HeLa knockdown cell lines (0.1 × 106) were transfected with vector or Flag-Vpr along with κB
(D), AP-1 (E), or HIV-1 LTR (F) luciferase reporter plasmids. After forty-eight hours, luciferase activities were measured. The activation fold by Vpr was
calculated by dividing the luciferase activity from Vpr-transfected cells by the luciferase activity from vector-transfected cells. The results shown are the
averages of three independent experiments. The error bars indicate standard deviations. *P < 0.05, **P < 0.01 (paired t test).
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gether, these data demonstrate that TAK1 is involved in
the replication of HIV-1 in a Vpr-dependent manner.
In further support of the dependence on TAK1 for Vpr
to activate NF-κB and AP-1, we examined the effect of a
Vpr mutant called S79A, known to be crucial for the func-
tion of Vpr [49]. We found that S79A lost its interaction
with TAK1 (Figure 7A). Furthermore, S79A was unable to
enhance TAK1 phosphorylation (Figure 7B). To further
confirm this finding, we mutated sernine 79 of Vpr in the
context of the pNLENY1-ES (WT) proviral DNA clone
and generated pNLENY1-ES S79A. We then produced
VSV-G pseudotyped HIV-1 virus particles by transfecting
HEK293T cells with proviral DNA clones together with
the pVSV-G DNA (Figure 7C). Next, we used the same
amounts of viruses WT, ΔVpr and S79A to infect Jurkat
cells and examined the phosphorylation of TAK1. The S79A
virus was unable to induce the phosphorylation of TAK1
(Figure 7D). In addition, S79A failed to stimulate NF-κB- or
AP-1-dependent luciferase expression (Figure 7E). Together,
we conclude that activation of TAK1 by Vpr leads to stimu-
lating NF-κB and AP-1-dependent gene expression.Discussion
HIV-1 Vpr plays an important role in viral replication and
pathogenesis. It has been well established that Vpr can ac-
tivate both NF-κB and AP-1 signaling [16-19,50], but how
Vpr regulates these cascades remains unclear. In this
study, we have identified TAK1 as an important player in
Vpr-mediated NF-κB and AP-1 signaling. We present data
showing that virion-associated Vpr enhances the phos-
phorylation of TAK1 by increasing TAK1 polyubiquitina-
tion through strengthening the association of TAB3 with
TAK1.
Many viruses have been reported to modulate the ac-
tivity of TAK1 and thereby the NF-κB and AP-1 path-
ways in order to benefit viral replication. For example,
the X protein of hepatitis B virus, LMP1 of Epstein-Barr
virus, vGPCR of KHSV, ICP0 of herpes simplex virus type
1, and Tax of human T cell leukemia virus type 1 activate
NF-κB or AP-1 signaling by targeting TAK1 [51-55].
TAK1 has also been identified as an important upstream
signaling molecule that RSV assimilates to activate NF-κB
and AP-1 [56]. Recently, it was reported that HIV-1 gp41
activates NF-κB signaling via a direct interaction with
Figure 7 The S79A mutant of Vpr is unable to activate NF-κB and AP-1. (A) Vpr S79A failed to associate with endogenous TAK1. HEK293T
cells (4 × 106) were transfected with wild type Flag-Vpr or its mutant S79A. After forty-eight hours, cell lysates were immunoprecipitated with
anti-Flag antibody. Samples from both cell lysates and immunoprecipitates were probed with rabbit anti-TAK1 and anti-Flag antibodies. (B) Vpr
S79A was unable to enhance the phosphorylation of TAK1. A total of 0.5 × 106 HEK293T cells were transfected with wild type Flag-Vpr or its
mutant S79A. After forty-eight hours, cells were pretreated with 20 nM Calyculin A for 5 min. Whole cell lysates were subjected to Western
blotting and probed with indicated antibodies. (C) HEK293T cells (4 × 106) were transfected with 1 μg pVSV-G along with 8 μg NLENY1-ES (WT),
NLENY1-ΔVpr (ΔVpr), or NLENY1-S79A (S79A) by PEI. The cell lysates and viral supernatants were subjected to Western blotting with the indicated
antibodies. (D) Jurkat cells (2 × 106) were infected with VSV-G pseudotyped WT, ΔVpr, or S79A equivalent to 500 ng p24 in the presence of 5
μg/ml polybrene by spinoculation at 300 xg for 30 min. After two hours, cells were pretreated with 15 nM Calyculin A for 5 min. Whole cell
lysates were subjected to Western blotting with the indicated antibodies. (E) Ser-79 is required for Vpr-induced NF-κB, AP-1, and HIV-1 LTR
activation. HeLa cells (0.1 × 106) were transfected with Flag-Vpr or its S79A mutant along with κB, AP-1, or HIV-1 LTR luciferase reporter plasmid.
After forty-eight hours, luciferase activities were measured. The results shown are the averages of three independent experiments. The error bars
indicate standard deviations. *P < 0.05, **P < 0.01 (paired t test).
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cells and facilitate HIV-1 replication [48]. For the first
time, we report that HIV-1 virion-associated Vpr associ-
ates with TAK1 and enhances the phosphorylation of
TAK1 (Figure 1). We noted that knockdown of TAK1
does not completely prevent Vpr from activating NF-κB
or AP-1 (Figure 6D). This is likely because Vpr may also
activate these two important transcription factors by
modulating other signaling pathways. An incoming HIV-1
particle carries up to 250-700 copies of Vpr protein and
only about 7-16 envelope trimmers [6,57,58]. Compared
with the small number of gp41, the relatively abundant
virion-associated Vpr protein is expected to be more ef-
fective in activating TAK1 and NF-κB. Indeed, using VSV-
G pseudotyped HIV-1 to infect cells, we found that Vpr
alone, in the absence of gp41, is able to activate TAK1
(Figure 1B-E).Recent studies showed that two cellular restriction fac-
tors, TRIM5 and tetherin, act as innate immune sensors
to detect retroviral infection. Both restriction factors acti-
vate TAK1, followed by stimulating the expression of NF-
κB and AP-1-dependent genes [59,60]. Given that HIV-1
benefits from activation of TAK1 by Vpr at the early stage
of HIV-1 infection, it is possible that TAK1 is activated via
different mechanisms by Vpr or TRIM5/tetherin. As a re-
sult, the downstream signaling and resulting gene expres-
sion profiles differ in regard to either facilitate HIV-1
replication (in the case of Vpr) or suppress HIV-1 replica-
tion (in the case of TRIM5/tetherin). It is also possible
that Vpr competes with TRIM5/tetherin for binding to
TAK1 and therefore counters innate immune response.
In addition to regulating the phosphorylation of TAK1,
we also found that Vpr can enhance the polyubiquitina-
tion of TAK1 by recruiting TAB3 (Figure 5). It is possible
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complexes, and therefore enhances TRAF6-mediated
K63-linked polyubiquitination of TAK1. We also found
that polyubiquitination of TAK1 is crucial for its phos-
phorylation and activation (Figure 4B and C). Several ly-
sine residues within TAK1, including Lys-34, Lys-158, and
Lys-209, have been reported to be ubiquitinated in re-
sponse to various stimuli [41,43-47]. Of these three ly-
sines, Lys-158 and Lys-209 are located in the kinase
domain of TAK1 and are essential in the polyubiquitina-
tion and activation of TAK1, with Lys-158 playing a major
role (Figure 4B). These data support the notion that poly-
ubiquitination of TAK1 may cause conformational change
of the TAK1 that exposes the critical phosphorylation site
(Thr-187) in the activation loop of TAK1 for auto-
phosphorylation.
Several viral proteins have been reported to co-opt cel-
lular signaling molecules. For example, HTLV-1 Tax pro-
tein constitutively activates NF-κB by directly interacting
with NEMO in viral infected T lymphoma cell lines [61].
Recently, it was demonstrated that Tax interacts with
TAK1 and recruits IKK complex to TAK1 [62,63]. In a
similar fashion, we previously showed that Vpr activates
both canonical and noncanonical NF-κB signaling by en-
hancing the phosphorylation of IKK complex [50]. Results
in this study further show that TAK1 is the upstream
kinase that is activated by Vpr and subsequently acts on
IKK/NF-κB pathway. Activation of both NF-κB and AP-1
signaling suffice to enhance LTR-dependent viral gene ex-
pression and up-regulate the expression of several cyto-
kines, such as IL-6, IL-8, and CCL5 [16-18]. This may
facilitate the virus to establish a productive infection at
the very early stage.
Conclusions
In summary, results of this study demonstrate the role
of TAK1 in Vpr-induced NF-κB and AP-1 activation.
Vpr itself is able to enhance the phosphorylation and
polyubiquitination of TAK1, and as a result, activates
HIV-1 LTR promoter. These results support an import-
ant role of Vpr in assisting HIV-1 to establish productive
infection by elevating early viral gene expression through
modifying the cellular environment.
Methods
Plasmids
The DNA constructs Myc-TAK1, HA-TAB1, HA-
TRAF6, HA-IKKβ, 3 × NF-κB-Luc, 7 × AP-1-Luc, and
HIV-1 LTR-Luc were described previously [50,55,64-66].
The DNA constructs T7-TAB3 were gifts from Giichi
Takaesu (Center for Integrated Medicine Research, School
of Medicine, Keio University, Japan) [26]. The pCDNA-
Flag Vpr (Flag-Vpr) construct was kindly provided by
Kuan-Teh Jeang (Molecular Virology Section, Laboratoryof Molecular Microbiology, National Institutes of Allergy
and Infectious Diseases, USA) [67]. Plasmid pcDNA-
FLAG Vpr was constructed by PCR amplification of
pNL4-3 Vpr and cloning of PCR products into pCDNA3.1
vector.
The DNA construct pcDNA3-Vpr was generated by
overlap PCR using pCDNA-Flag Vpr as a template. The
coding sequence of human full length MKK7 was ampli-
fied from HEK293T cDNA, then cloned into the pCMV-
HA expression vector (Clontech).
Myc-TAK1 K34R, K158R, K209R and Flag-Vpr S79A
were generated using PCR-based mutagenesis. The PCR
primers are listed in Additional file 1: Table S1.
The pNLENY1-ES-IRES DNA construct was kindly pro-
vided by David Levy [68]. This HIV-1 DNA was derived
from the NL4-3 strain by inserting two-stop codons into
the envelope gene. The enhanced yellow fluorescent pro-
tein (YFP) sequence was inserted between the env and nef
ORFs. An internal ribosome entry sequence (IRES) was
inserted upstream of nef to direct the expression of Nef.
All accessory genes are left intact. The HIV-1 Luc was a
gift from Johnny J He [69]. This proviral DNA construct
was derived from the NL4-3 strain with env gene inacti-
vated and the firefly luciferase (Luc) gene in place of HIV-
1 nef. The pNLENY1-ΔVpr and pHIV-Luc ΔVpr were
derived from pNLENY1-ES-IRES or pHIV-Luc by mutat-
ing the start codon ATG of vpr gene [50]. The pNLENY1-
S79A was generated with PCR-based mutagenesis using
primers listed in Additional file 1: Table S1.
All DNA constructs used in this study were verified by
sequencing.
Cell culture and transfection
HeLa and HEK293T cells were maintained in Dulbecco’s
modified Eagle’s medium (high glucose) supplemented
with 10% FBS (Gibco), 100 U/ml penicillin/streptomycin
(Invitrogen). Jurkat, THP-1 and human peripheral blood
mononuclear cells (PBMCs) were maintained in RPMI
1640 supplemented with 10% FBS, 100 U/ml penicillin/
streptomycin, 2.4 mM L-glutamine. Cells were maintained
in a humidified atmosphere containing 5% CO2 at 37°C.
HeLa and HEK293T were transfected by PEI (Poly-
sciences) or Lipofectamine 2000 (Invitrogen) in accord-
ance with the manufacturer’s instructions.
PBMCs were isolated from buffy coat from healthy
blood donors by histopaque and percoll gradient centri-
fugation, and were activated with phytohemagglutinin
(PHA; 5 mg/ml) (Sigma) and IL-2 (20 U/ml) (PeproTech)
for 24 h before virus infection.
To differentiate THP-1 monocytes into macrophage-
like cells, THP-1 cells were seeded at a concentration of
1 × 106 cells/ml in 1.5 ml fresh cell culture medium con-
taining 200 ng/ml tetradecanoylphorbol acetate (PMA)
(Sigma). After twenty-four hours, cell culture media
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for an additional 48 hours before use.
Antibodies and reagents
Anti-phospho-TAK1 (Thr-187), rabbit anti-TAK1, anti-
TRAF2, anti-TRAF6, anti-TAB1, anti-TAB2, anti-phospho-
IKKα/β (Ser176/180), anti-phospho-MKK7 (Ser-271/
Thr-275), and anti-MKK7 antibodies were purchased
from Cell Signaling Technology. Anti-TAB3 antibody
was from Abcam. Anti-Myc antibody, normal mouse
IgG and normal rabbit IgG were from Millipore. Anti-
Flag antibody (M2) was obtained from Sigma. Anti-HA,
anti-α-Tubulin, and horseradish peroxidase-conjugated
secondary antibodies were from Santa Cruz Biotechnol-
ogy. Rabbit anti-Vpr antibody was provided by National
Institutes of Health (NIH) AIDS Research and Refer-
ence Reagent Program. Mouse anti-p24 and anti-TAK1
were generated by immunizing mice with the corre-
sponding full length proteins purified form E. coli BL21
(DE3). 4′, 6-diamidino-2-phenylindole (DAPI) and PMA
were purchased from Sigma. Fluorescein-conjugated anti-
mouse and anti-rabbit secondary antibodies were pur-
chased from Jackson ImmunoResearch Laboratories.
Serine/Threonine phosphatase inhibitor Calyculin A was
purchased from Cell Signaling Technology.
Generation of stably transduced cell lines
First, shRNA oligos targeting TAK1, TAB3, and TRAF6
were designed by shRNA Sequence Designer (Clontech).
Double-stranded oligonucleotides corresponding to the
target sequences were cloned into the pSIREN-RetroQ
(Clontech). The target sequences were as follows, shCon-
trol (without specific target in cells) (GACAGAACCA-
GAGGATAGA), TAK1 (AGGCAAAGCAACAGAGTGA),
TAB3 (CCTTCACCCATCAGTAATC), TRAF6 (GCCTG
GATTCTACACTGGCAAA), and TRAF2 (GGACCAA-
GACAAGATTGA A).
Then, retrovirus particles were prepared by transfect-
ing HEK293T cells with 1 μg pMLV-Gag-Pol, 0.5 μg
pVSV-G and 1 μg pSIREN-RetroQ DNA constructs.
After forty-eight hours, supernatants were collected and
centrifuged at 3,000 rpm to remove cell debris. HeLa
cells were infected with the harvested virus particles in
the presence of 5 μg/ml polybrene by spinoculation at
450 × g for 30 min at room temperature. Forty-eight
hours after infection, cells were subcultured in selection
medium containing 2 μg/ml puromycin (Sigma). Knock-
down efficiency was assessed by Western blotting using
specific antibodies.
Viruses and infections
Infection with VSV-G pseudotyped HIV-1 viruses were
performed as we previously described [50]. Briefly, theviruses were produced by transfecting HEK293T cells with
plasmid DNA pVSV-G, and pNLENY1-ES-IRES or
pNLENY1-ΔVpr. After forty-eight hours, the viral super-
natants were collected, and the virus titer was determined
by ELISA (Biomerieux) to quantify viral p24 amounts.
The viruses (equivalent to 500 ng p24) were used to infect
Jurkat, THP-1, THP-1 differentiated macrophage, and
PBMC in the presence of 5 μg/ml polybrene by spinocula-
tion in 1.6 ml fresh medium. After two hours, the infected
cells were harvested to detect HIV-1-induced phosphoryl-
ation of endogenous TAK1.
Protein phosphorylation analysis
At 2 hours post-infection or 48 hours post-transfection,
cells were harvested by centrifugation at 1000 × g for 3
min at 4°C, washed twice with ice-cold 1xphosphate-
buffered saline, and suspended in 70 μl lysis buffer (20 mM
Tris (pH 7.4), 150 mM NaCl, 2 mM EDTA, 1% Triton-X-
100, 1 mM sodium orthovanadate, 50 mM sodium fluoride,
phosphatase inhibitor mixture tablet (Roche), protease
inhibitor cocktail tablets complete, EDTA-free (Roche)),
and chilled on ice for 30 min with frequent agitation. Cell
lysates were collected by centrifugation at 13,000 × g for 10
min at 4°C. The supernatants were separated by SDS-
PAGE and subjected to Western blotting.
Immunoprecipitation
For protein-protein interaction analysis, HEK293T cells
were washed twice with ice-cold 1xphosphate-buffered sa-
line, and lysed in lysis buffer (50 mM Tris (pH 7.4), 150
mM NaCl, 2 mM EDTA, 3% Glycerol, 1% NP-40, protease
inhibitor cocktail tablets complete, EDTA-free(Roche)).
The cell lysates were sonicated and centrifuged at
13,000 × g for 10 min at 4°C. To detect the polyubiquiti-
nated form of TAK1 and TRAF6, in vivo ubiquitination
assay were performed as follows. Cells were lysed in 0.4
ml TNET buffer (20 mM Tris (pH 7.4), 150 mM NaCl,
5 mM EDTA, 1% Triton-X-100). Supernatants were de-
natured in 1% SDS by boiling for 15 min to remove non-
covalently attached proteins, and then diluted to 0.1%
SDS with regular TENT buffer. Then, supernatants
were incubated with indicated antibody for 3 h at 4°C
and rotated with Protein A-agarose (Millipore) for 3 h
or overnight (for endogenous protein immunoprecipita-
tion) at 4°C. After six times washes with lysis buffer, the
immunoprecipitated materials were boiled in 40 μl 2 ×
SDS loading buffer and subjected to Western blotting.
Western blotting
Cell lysates or immunoprecipitated materials were resolved
by SDS-PAGE and transferred to a PVDF membrane (GE
Healthcare). The membranes were blocked in 5% non-fat
milk-TBS for 45 min at room temperature, and probed with
indicated primary antibodies overnight at 4°C. After
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goat anti-mouse secondary antibody, enhanced chemilu-
minescence reagents (Millipore) were used for signal detec-
tion with X-ray film.
Immunofluorescence microscopy assay (IFA)
Indirect IFA was performed as we previously described
[50]. HeLa cells grown on poly-lysine-coated glass slides
were first fixed with 4% paraformaldehyde in PBS for 10
min and then permeabilized with 0.1% Triton X-100 in
PBS for 10 min. After incubation in the blocking buffer
containing 3% BSA and 6% skim milk, cells were stained
with anti-Flag or anti-Myc primary antibodies (1:100 di-
lution, 2 h at room temperature) followed by FITC- or
TRITC-conjugated secondary antibodies (1:100 dilution,
45 min at room temperature). DAPI was utilized to stain
nuclei. Images were captured using Leica TCS SP5 laser
scanning confocal microscope.
Luciferase assay
HeLa RNAi cell lines were seeded at a concentration of
0.1 × 106 cells/well. The next day, cells were transfected
with indicated reporter gene and Flag-Vpr DNA along
with the Renilla luciferase DNA. After forty-eight hours,
luciferase activity was measured with a Dual-Luciferase
reporter assay system according to the manufacturer’s
instructions (Promega). The relative luciferase activity
was calculated by dividing the firefly luciferase activity
by the Renilla luciferase activity. Three independent
transfection experiments were performed.
Statistical analysis
Data were presented as mean values ± SD of at least
three independent experiments. Statistical comparison of
Vpr-transfected cells with matched control cells was per-
formed using F-test and Student’s T-test. P values of
<0.05 were considered to be statistically significant.
Additional file
Additional file 1: Figure S1. Vpr increased the phosphorylation of
TAK1 in the absence of viral genome. Figure S2. TAK1 is involved in the
replication of HIV-1. Table S1. List of primers used in mutagenesis and
cloning.
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